Directed new share issue in Oasmia Pharmaceutical AB (SE) — SEK 72 million

Carnegie acted as adviser and sole book-runner in the directed new share issue of 3.8 million new shares at a subscription price at SEK 19 per share. Oasmia develops novel formulations of already established cytostatics for both human and veterinary use, which in comparison to current alternatives show improved performance, a reduced side-effect profile and an expanded therapeutic area.March 2014.